Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study
Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling studyCost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study, Published online: 20 August 2018; doi:10.1038/s41391-018-0076-3Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study
Source: Prostate Cancer and Prostatic Diseases - Category: Urology & Nephrology Authors: Tim M. Govers Daphne Hessels Virginie Vlaeminck-Guillem Bernd J. Schmitz-Dr äger Christian G. Stief Claudio Martinez-Ballesteros Matteo Ferro Angel Borque-Fernando Jose Rubio-Briones J. P. Michiel Sedelaar Wim van Criekinge Jack A. Schalken Source Type: research